89 related articles for article (PubMed ID: 9674852)
21. In leukapheresis products from non-Hodgkin's lymphoma patients, the immature hematopoietic progenitors show higher CD90 and CD34 antigenic expression.
Villaron EM; Almeida J; Lopez-Holgado N; Sanchez-Guijo FM; Alberca M; Blanco B; Sanchez-Abarca LI; Lopez O; Perez-Simon JA; San Miguel JF; del Cañizo MC
Transfus Apher Sci; 2007 Oct; 37(2):145-56. PubMed ID: 17983836
[TBL] [Abstract][Full Text] [Related]
22. High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy.
Molina A; Krishnan AY; Nademanee A; Zabner R; Sniecinski I; Zaia J; Forman SJ
Cancer; 2000 Aug; 89(3):680-9. PubMed ID: 10931469
[TBL] [Abstract][Full Text] [Related]
23. Circulating progenitors following high-dose sequential (HDS) chemotherapy with G-CSF: short intervals between drug courses severely impair progenitor mobilization.
Tarella C; Caracciolo D; Gavarotti P; Bondesan P; Cherasco C; Omedè P; Bregni M; Siena S; Gianni AM; Pileri A
Bone Marrow Transplant; 1995 Aug; 16(2):223-8. PubMed ID: 7581140
[TBL] [Abstract][Full Text] [Related]
24. Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol.
Jantunen E; Mahlamäki E; Nousiainen T
Bone Marrow Transplant; 2000 Oct; 26(7):737-41. PubMed ID: 11042654
[TBL] [Abstract][Full Text] [Related]
25. Quantitation of primitive and lineage-committed progenitors in mobilized peripheral blood for prediction of platelet recovery post autologous transplant.
Hogge DE; Lambie K; Sutherland HJ; Benny WB; Dalal B; Currie C; Barnett MJ; Eaves AC; Eaves CJ
Bone Marrow Transplant; 2000 Mar; 25(6):589-98. PubMed ID: 10734292
[TBL] [Abstract][Full Text] [Related]
26. Prospective randomized comparative observation of single- vs split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin's lymphoma.
Kim S; Kim HJ; Park JS; Lee J; Chi HS; Park CJ; Huh J; Suh C
Ann Hematol; 2005 Oct; 84(11):742-7. PubMed ID: 16132903
[TBL] [Abstract][Full Text] [Related]
27. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma.
Pavone V; Gaudio F; Guarini A; Perrone T; Zonno A; Curci P; Liso V
Bone Marrow Transplant; 2002 Feb; 29(4):285-90. PubMed ID: 11896424
[TBL] [Abstract][Full Text] [Related]
28. Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells.
Witzens-Harig M; Heilmann C; Hensel M; Kornacker M; Benner A; Haas R; Fruehauf S; Ho AD
Stem Cells; 2007 Jan; 25(1):228-35. PubMed ID: 17204607
[TBL] [Abstract][Full Text] [Related]
29. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
[TBL] [Abstract][Full Text] [Related]
30. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
31. Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
Clavio M; Garrone A; Pierri I; Michelis GL; Balocco M; Albarello A; Varaldo R; Canepa P; Miglino M; Ballerini F; Canepa L; Gobbi M
Oncol Rep; 2005 Oct; 14(4):933-40. PubMed ID: 16142354
[TBL] [Abstract][Full Text] [Related]
32. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma.
Stiff P; Gingrich R; Luger S; Wyres MR; Brown RA; LeMaistre CF; Perry J; Schenkein DP; List A; Mason JR; Bensinger W; Wheeler C; Freter C; Parker WRL ; Emmanouilides C
Bone Marrow Transplant; 2000 Sep; 26(5):471-81. PubMed ID: 11019835
[TBL] [Abstract][Full Text] [Related]
33. Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 x 5 microg/kg) compared to a single dose (1 x 10 microg/kg).
Kröger N; Zeller W; Hassan HT; Krüger W; Gutensohn K; Löliger C; Zander AR
Bone Marrow Transplant; 1999 Jan; 23(2):125-9. PubMed ID: 10197796
[TBL] [Abstract][Full Text] [Related]
34. A randomized comparison of peripheral blood hematopoietic progenitor cell level of 5/mm3 versus 50/mm3 as a surrogate marker to initiate efficient autologous blood stem cell collection.
Kim MK; Kim S; Jang G; Lee SS; Sym SJ; Lee DH; Kim SW; Jang S; Park CJ; Chi HS; Huh J; Suh C
J Clin Apher; 2007; 22(5):277-82. PubMed ID: 17880017
[TBL] [Abstract][Full Text] [Related]
35. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S
Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420
[TBL] [Abstract][Full Text] [Related]
36. Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma.
Magagnoli M; Sarina B; Balzarotti M; Castagna L; Timofeeva I; Nozza A; Bertuzzi A; Siracusano L; Sinnone M; Santoro A
Bone Marrow Transplant; 2001 Nov; 28(10):923-7. PubMed ID: 11753545
[TBL] [Abstract][Full Text] [Related]
37. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
[TBL] [Abstract][Full Text] [Related]
38. Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization.
Reiser M; Josting A; Draube A; Mapara MY; Scheid C; Chemnitz J; Tesch H; Wolf J; Diehl V; Söhngen D; Engert A
Bone Marrow Transplant; 1999 Jun; 23(12):1223-8. PubMed ID: 10414907
[TBL] [Abstract][Full Text] [Related]
39. Collection of hematopoietic stem cells from patients with autoimmune diseases.
Burt RK; Fassas A; Snowden J; van Laar JM; Kozak T; Wulffraat NM; Nash RA; Dunbar CE; Arnold R; Prentice G; Bingham S; Marmont AM; McSweeney PA
Bone Marrow Transplant; 2001 Jul; 28(1):1-12. PubMed ID: 11498738
[TBL] [Abstract][Full Text] [Related]
40. Progenitor and lymphoma cells in blood stem cell harvests: impact on survival following transplantation.
Demirkazik A; Kessinger A; Armitage JO; Bierman PJ; Lynch J; Vose J; Chan W; Sharp JG
Bone Marrow Transplant; 2001 Jul; 28(2):207-12. PubMed ID: 11509940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
